LONDON, (1 August 2023) – Bioxydyn, Ltd. and Queen Square Analytics Ltd. today announced a strategic partnership to provide advanced clinical trial services in the neurological treatment arena.
As partners, Bioxydyn and QSA will jointly provide a comprehensive set of clinical trial services for multiple sclerosis (MS) and other neurological disorders. The offering includes:
Bioxydyn provides high-standard, quantitative MR imaging services to both the pharmaceutical industry and clinical/academic R&D. With over a decade of experience delivering complex, multi-centre clinical trials, Bioxydyn employs robust GxP and 21 CFR Part 11 compliant processes, supported by their cloud-based VoxelFlow data management & analysis platform. Bioxydyn empowers its clients with unique insights into disease progression and drug effects, helps pharmaceutical companies make investment decisions and assists clinicians in developing the best treatment for patients.
Queen Square Analytics offers comprehensive capabilities in contract research for neurological clinical trials, with a focus on multiple sclerosis (MS). Our team has a collective experience of more than a century in MS clinical trials and neurological disorders.